Cell-specific mRNA and gene editing therapies

We overcome the biggest challenge for genetic medicines: Safe and effective delivery. Based on an extensive library of scalable non-immunogenic materials and a data-driven screening approach, we modulate novel nanocarriers to intravenously deliver large genetic payloads into specific cells.

We apply our proprietary delivery technology to develop mRNA and gene editing therapies for currently incurable diseases. Our pipeline includes immunotherapies, which we strive to advance rapidly into the clinic.


© 2022 Nuntius Therapeutics.

Nuntius Therapeutics, Inc.

San Francisco, United States

Nuntius Therapeutics Ltd.

London, United Kingdom